Statutory status
Check the current code and recent session laws. State law may address controlled substances, research authorization, or agency duties, while federal scheduling remains in force.
United States · policy notes
State Map
A careful, jurisdiction-by-jurisdiction view of ibogaine’s U.S. legal reality: federal status first, then the state bills, research conversations, and public funding signals that can change the local picture.
Last updated: September 13, 2026
01 / baseline
The rule that sits above every state line
Ibogaine is federally controlled in the United States. The U.S. Drug Enforcement Administration’s controlled-substances schedule lists ibogaine as a Schedule I substance. That federal status is the starting point for every jurisdiction on this page: a state policy discussion, research proposal, or appropriations debate does not by itself make domestic ibogaine treatment lawful.
State laws can create different enforcement environments, authorize studies, direct agencies to examine policy, or appropriate money for research. They cannot remove federal scheduling. This distinction matters when evaluating claims about ibogaine detox centers or purported domestic access: a local business description is not proof of a lawful treatment pathway.
The broader legal and research overview explains the difference between controlled-substance law, FDA-regulated research, and treatment marketing. For general background, the ibogaine entry is a useful starting point, but official statutes, agency notices, and study records should control any current legal conclusion.
02 / state notes
A map of signals, not a map of clinics
Across all 50 states and the District of Columbia, federal Schedule I status remains the central statutory constraint. The most useful state-level question is therefore not “where is ibogaine legal?” but “what specific action, if any, has the jurisdiction taken on research, derivatives, funding, or policy review?” A careful search begins with the state legislature, a governor’s office, a state health agency, and the relevant university or trial registry.
Arizona has been part of public conversations about ibogaine policy and research, but those conversations should not be confused with authorization for treatment. Anyone encountering claims around ibogaine treatment in Arizona should verify the current statute and the exact status of any named study with official sources before treating it as a legal option.
Texas has also appeared in policy discussions concerning possible research support and alternatives for substance-use harms. The policy context behind Texas governor ibogaine discussions requires the same caution: public interest or proposed funding is not a blanket exception to federal law. The National Institutes of Health maintains ClinicalTrials.gov, where registered studies can be checked by intervention, sponsor, and location.
Other states may have no ibogaine-specific measure at all, may have only a proposal that did not advance, or may have broad psychedelic-policy discussions that do not name ibogaine. Those categories should not be collapsed. A research task force is different from an enacted appropriation; an enacted appropriation is different from a regulatory program; and none alone establishes routine domestic treatment access.
03 / proof list
What to check in every jurisdiction
Research activity
Look for a named sponsor, protocol, institutional review process, and trial record. A clinic advertisement is not equivalent to an authorized study.
Public funding
Read enacted budget language and agency notices. An announced initiative, a requested appropriation, and released funding are separate policy events.
Derivative claims
Do not assume a reference to an ibogaine derivative changes the legal analysis. Exact compounds, study protocols, and agency status all matter.
For claims involving addiction treatment, the federal regulatory framework is especially important. The U.S. Food and Drug Administration explains that investigational new drug applications are part of the process for studying unapproved drugs in humans. That is a research pathway, not an endorsement of retail or clinic-based treatment claims.
Costs and travel language can also obscure the legal question. Pages discussing ibogaine retreat cost, ibogaine cost, or an ibogaine clinic in Tijuana may concern settings outside the U.S.; they do not establish what is authorized in a particular state.
04 / keep the lines clear
Policy movement can be real and still incomplete
“A changing conversation is not the same thing as a changed law.”
The distinction is especially important for people affected by opioid use. Material about ibogaine for opioid addiction may describe a serious public-health concern, but it should never substitute for official legal status, medical evaluation, or evidence about risk. Ibogaine has documented safety concerns, including cardiac risk, and this page is not treatment guidance.
Comparisons can add context but not legal clarity. Discussion of ibogaine versus ayahuasca involves substances with different histories, laws, and research questions; the legal status of one cannot be inferred from the other. Similarly, personal narratives such as an ibogaine trip report are not authoritative evidence of state authorization or clinical safety.
International references need their own legal review. Information about an ibogaine treatment center in Europe describes a different legal and regulatory setting, not a route around U.S. federal or state rules. For a plain-language account of this resource’s approach to legal uncertainty and sourcing, see the independent resource principles.
05 / field questions
Questions the map should answer
Is ibogaine legal in any U.S. state?
Federal Schedule I status remains the controlling nationwide baseline. State legislation may affect research, funding, or policy review, but it does not itself make routine domestic ibogaine treatment lawful.
Does a state research initiative mean treatment is available?
No. Research activity can be limited to a particular protocol, site, sponsor, and participant group. Verify a study through official records and do not infer a general treatment exception from an initiative or announcement.
How often should a state policy page be checked?
Check before relying on it. Legislation can be introduced, amended, enacted, vetoed, funded, paused, or superseded. Review current legislative records and agency publications rather than relying on dated promotional claims.
Use the record
Start with the statute. Then check the study. Then pause.
This map is an evergreen legal and policy reference, not treatment guidance. It is designed to help separate official action from marketing language, especially where fast-moving bills and research announcements can sound more settled than they are. For a fuller view of the site’s scope, the legal-context resources explain how to approach claims without treating them as medical or legal advice.